SK Bioscience has reported an increase in revenue and a reduction in operating losses for the third quarter of this year.
The company announced on November 5 that its consolidated revenue for Q3 reached 182.4 billion won, a 21% increase compared to the same period last year. During the same timeframe, operating losses decreased to 11.2 billion won, down 42%. Pre-tax profit turned positive at 6.1 billion won.
SK Bioscience stated, "The operating loss is at its lowest level in the last 11 quarters, despite ongoing investments in research and development (R&D) and production infrastructure. The improvement in performance was influenced by the growth of our subsidiary IDT Biologika and the expansion of sales for both our own vaccines and licensed vaccines."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.